China to stop investing in U.S. biotech …
China to stop investing in U.S. biotech
China's Fosun pulls back from U.S. biotech scene
Fosun is pulling back from the U.S. biotech sector in response to the escalating trade war with China. The Chinese conglomerate has struck deals with Kite Pharma, Revance Therapeutics and other U.S. biotechs in the past but now plans to limit its activities in the country.